Krystexxa

Free

Trade Name Krystexxa
Molecule Pegloticase
Strength 8mg/mL
Type/Form IV infusion
Manufacturer Horizon Therapeutics
Categories: , Brand:

Description

In individuals with glucose-6-phosphate dehydrogenase deficiency, pegloticase may precipitate a severe, life-threatening hemolysis with methemoglobinemia; it is therefore contraindicated in such individuals. Pegloticase may also show immunogenicity, which can be diminished by co-administration with methotrexate.

Reviews

There are no reviews yet.

Be the first to review “Krystexxa”

Your email address will not be published. Required fields are marked *